Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 7,009 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Terminated Not applicable Interventional

Connected Catheter- Safety and Effectiveness Study

NCT03843073
View directory record Official record
Conditions
Urinary Retention, Neurogenic Bladder, Urologic Diseases
Interventions
Connected Urinary Catheter
Device
Lead sponsor
Spinal Singularity
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Downey, California • Inglewood, California • Murrieta, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Phosphate Kinetic Modeling

NCT01003223
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia
Interventions
Computer algorithm management of hyperphosphatemia
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 17, 2026, 5:36 PM EDT
Not listed Phase 3 Interventional

SystemCHANGE: An Intervention for Medication Change in Adult Kidney Transplant Patients

NCT02416479
View directory record Official record
Conditions
Kidney Disease
Interventions
SystemCHANGE, Patient-education attention control
Behavioral
Lead sponsor
Cynthia Russell
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

NCT06715670
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Zibotentan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 5:36 PM EDT
Recruiting Phase 3 Interventional

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723
View directory record Official record
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Placebo/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
133
States / cities
Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

NCT01239342
View directory record Official record
Conditions
Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
8
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

NCT00262886
View directory record Official record
Conditions
Kidney Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

NCT00853242
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Placebo, Genz-644470, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
52
States / cities
Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Muscle Progenitor Cell Therapy for Urinary Incontinence

NCT01953315
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Autologous Muscle Progenitor Cells
Biological
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 17, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional

NAD Augmentation in Diabetes Kidney Disease

NCT05759468
View directory record Official record
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

FREEOAB Study for Overactive Bladder

NCT04547920
View directory record Official record
Conditions
Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
Interventions
Wearable Bladder Modulation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 17, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Autologous alpha-DC1/TBVA vaccine, Cabozantinib
Biological · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Seattle Cardiorenal Remote Ischemic Preconditioning Trial

NCT01260259
View directory record Official record
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass, Myocardial Injury, Acute Kidney Injury, Acute Lung Injury
Interventions
RIPC, Control
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 17, 2026, 5:36 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial

NCT07604662
View directory record Official record
Conditions
Acute Kidney Injury, Surgery Complications, Anesthesia
Interventions
EHR-Embedded AKI Risk Score, EHR-Embedded AKI Risk Score with Best Practice Advisory
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25,518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646
View directory record Official record
Conditions
FSGS
Interventions
DMX-200, Placebo
Drug
Lead sponsor
Dimerix Bioscience Pty Ltd
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-930
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Solace Stress Urinary inContinence Control Efficacy and Safety Study

NCT02210273
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Solace Bladder Control (Vesair) Balloon, Solace Sham Treatment
Device
Lead sponsor
Solace Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Non-Invasive Evaluation of Transplant Kidney Using OCT

NCT02084966
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Procedure/Surgery: Transplantation: OCT of Kidney Transplant
Procedure
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 17, 2026, 5:36 PM EDT
Completed Not applicable Interventional

System Interventions to Achieve Early and Equitable Transplants (STEPS) Study

NCT05014256
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
STEPS Health System Outreach intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 5:36 PM EDT